May222017 Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome − Data Presented at Antiepileptic Drug Trials XIV 2017 Conference − May 22, 2017
May172017 Anavex President & CEO Christopher U. Missling, PhD, to present preclinical data on ANAVEX 2-73™ at the Epilepsy Foundation’s Antiepileptic Drug Trials XIV Conference on May 19. May 17, 2017
May12017 Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President of Regulatory Affairs May 1, 2017
Anavex President & CEO Christopher U. Missling, PhD, to participate in a roundtable discussion at the World Orphan Drug Congress USA, on April 21. April 21, 2017
Apr32017 Anavex Life Sciences Reports New Mechanism of Action Data Related to ANAVEX Compounds Targeting Sigma-1 Receptor April 3, 2017
The dual regulation of oxidative stress by SIGMA1 receptors in physiological or pathological conditions April 1, 2017
Targeting M1 muscarinic and sigma-1 receptors in Alzheimer’s disease: Reversal of pathological hallmarks and associated cognitive dysfunction in McGill-R-Thy1-APP rats March 30, 2017
Mar292017 Anavex Life Sciences to Present at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases AD/PD™ 2017 March 29, 2017
Mar152017 Anavex Life Sciences to Present at Oppenheimer 27th Annual Healthcare Conference March 15, 2017
Mar132017 Anavex Life Sciences to Present at 14th Annual BIO Asia International Conference March 13, 2017
